Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 272Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 74Head and Neck Neoplasms 69Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

pertuzumab 1Trastuzumab 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Positive Early Breast Cancer × Docetaxel × Clear all
NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Fudan University

Phase 3 Recruiting
1,406 enrolled
Breast

HER2 Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡